Donahue Kevin Michael — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Donahue Kevin Michael is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $258.83B.
Profile
Kevin Michael Donahue is identified in a 2026 SEC filing as a 10% owner of Mainz Biomed NV (MYNZ), a company focused on molecular genetic diagnostics and the ColoAlert colorectal cancer screening test. The filing shows no stock purchases or sales for the reporting period, establishing him as a significant shareholder as of 2026-01-16.
Role
10% Owner
Notability
15/100
Board memberships
Mainz Biomed NV
Awards & honors
Holds a 10% ownership stake in Mainz Biomed NV (MYNZ) as disclosed in the 2026 SEC filing
Kevin Michael Donahue is identified in a 2026 SEC filing as a 10% owner of Mainz Biomed NV (MYNZ), a company focused on molecular genetic diagnostics and the ColoAlert colorectal cancer screening test. The filing shows no stock purchases or sales for the reporting period, establishing him as a significant shareholder as of 2026-01-16.…
Has Donahue Kevin Michael been buying or selling stock?
Recorded transactions: 2 open-market purchases ($258.83B) and 0 open-market sales () across all tracked filings.
Where can I see all of Donahue Kevin Michael's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
